Streetwise Expert Interviews

Edward Stopke

Convert Catalysts into Profits: Sagient Research's Edward Stopke

The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview with The Life Sciences Report, Edward Stopke of Sagient Research unveils his list of companies with catalytic moments in the making.

(1/22/15) More >
Read More Streetwise Interviews

Oppenheimer Analyst Rohit Vanjani's 2015 Pipeline: Pot, Pain, and Babies

Building on another blockbuster year in specialty pharmacy and generics, Rohit Vanjani, a senior analyst at Oppenheimer & Co., has reason to be excited for 2015. (1/15/15) More >

Newsletter Briefs

"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) Athersys Inc. - The Life Sciences Report Interview with Edward Stopke More >

"The research synergy with Gilead and Merck could prove fruitful for RNN in terms of acquisition potential." (1/22/15) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Edward Stopke More >

"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) Neuralstem Inc. - The Life Sciences Report Interview with Edward Stopke More >

"RNN's RX-3117 showed the ability to stop tumor growth from 62–100%." (1/13/15) Rexahn Pharmaceuticals Inc. - Sharon di Stefano, Seeking Alpha More >

"The vote of confidence CTH has received from The Michael J. Fox Foundation is very advantageous." (1/8/15) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Daniel Pearlstein More >

"The new year holds a great deal of promise for the field of regenerative medicine, with companies like NEO at the forefront." (12/30/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >

"With OMER's product, surgeons will receive a better product from a single-source, FDA-regulated company." (12/30/14) Omeros Corp. - The Life Sciences Report Interview with Steve Brozak More >

"RNN has decent short-term momentum and is seeing solid activity on the earnings estimate revision front." (12/10/14) Rexahn Pharmaceuticals Inc. - Zacks Equity Research More >

Expert Analysis

"2014 was a successful year for INO." (1/17/15) Inovio Pharmaceuticals Inc. - Jason Russ, Seeking Alpha More >

"NHC's Q4/14 revenue of $39.2M was a significant positive surprise." (1/13/15) Nobilis Health Corp. - Keith Hinton, Sidoti & Company More >

"MSB started a Phase 3 trial in chronic lower back pain due to DDD." (1/15/15) Mesoblast Ltd. - Jason Kolbert, Maxim Group More >

"CUR is roughly on schedule with its clinical trials in four diseases." (1/13/15) Neuralstem Inc. - Larry Smith, SmithOnStocks More >

"NHC's estimated Q4/14 sales were up 109% versus those of Q4/13." (1/13/15) Nobilis Health Corp. - Steven Ralston, Zacks Small-Cap Research More >

"We view NBS's collaboration with Invetech positively and as a good fit." (1/13/15) NeoStem Inc. - Jason Kolbert, Maxim Group More >

"NHC's estimated Q4/14 revenue of $39.2M was well ahead of guidance." (1/12/15) Nobilis Health Corp. - Sheila Broughton, PI Financial More >

"We estimate ATHX's MultiStem to hit peak sales of $3B across the US, EU and Japan." (1/12/15) Athersys Inc. - Christian Glennie, Edison Investment Research More >